Comparison
BPC-157 vs. Retatrutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
2381089-83-2
Molecular weight
1419.5 g/mol
4731.6 g/mol
Half-life
4 h
144 h
Sequence
GEPPPGKPADDAGLVY-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
4
Effects recorded
4
4
Open conflicts
2
0
Documented adverse events
2
2